Suppr超能文献

Long term outcomes of thoracic endovascular repair versus optimal medical therapy for uncomplicated Stanford type B aortic dissection: a systematic review and meta-analysis.

作者信息

Qazi Shurjeel Uddin, Zaide Dua Batool, Fatima Urooj, Nayyab Durre, Hijab Nafia, Bajaj Simran, Majid Fariya, Nezami Maaz Syed, Mansoor Mustafa, Nabi Rayyan, Farhan Syed Ali

机构信息

Department of Surgery, Dow University of Heath Sciences, Karachi, Pakistan.

Department of Dialysis, Memon Hospital Karachi, Karachi, Pakistan.

出版信息

Future Cardiol. 2025 Sep 9:1-9. doi: 10.1080/14796678.2025.2557765.

Abstract

INTRODUCTION

The aim of this article is to compare the long-term efficacy of Thoracic Endovascular Aortic Repair (TEVAR) versus Optimal Medical Therapy (OMT) in reducing mortality among adult patients with uncomplicated Stanford type B aortic dissection (uSTBAD).

METHODS

An electronic search of PubMed, Cochrane Central and Google Scholar was conducted for studies comparing TEVAR with OMT for mortality in adult patients with uSTBAD. Relevant outcomes, including mortality, aortic rupture, re-intervention, retrograde type A dissection, myocardial infarction and stroke were analyzed and presented as risk ratios (RRs) along with their 95% confidence intervals (95% CI). A p-value of less than 0.05 was considered significant in all cases. All statistical analysis was conducted using Review Manager.

RESULTS

A total of 12 studies were included (n = 25,605). Meta-analysis favored TEVAR over OMT for all-cause mortality (RR = 0.57, 95% CI: [0.43-0.76]; P < 0.01). However, there was no significant difference considering the morbidity, which included endovascular re-intervention (RR = 0.76, 95%CI: [0.46-1.28]; P = 0.30), aortic rupture (RR = 0.38; 95%CI: [0.14-1.05]; P = 0.06), retrograde type A dissection (RR = 1.00; 95%CI: [0.78-1.28]; P = 1.00), myocardial infarction (RR = 0.85; 95% CI: [0.51-1.42]; P = 0.53). However, a significant increase in risk of stroke in TEVAR group was observed (RR = 1.56; 95%CI: [1.30-1.89]; P < 0.01).

CONCLUSION

We report that while there were similar morbidity outcomes for uSTBAD treated with TEVAR and OMT, overall mortality was significantly improved with TEVAR. Further large-scale studies are needed to elucidate the differences in outcomes between the two treatment options.

PROTOCOL REGISTRATION

https://www.crd.york.ac.uk/prospero identifier is CRD42024566452.

摘要

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验